Adma Biologics (ADMA) Liabilities and Shareholders Equity (2011 - 2025)

Adma Biologics' Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $624.2 million for Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 27.74% year-over-year to $624.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 billion (up 40.79% YoY) and the FY2025 annual result came in at $624.2 million, up 27.74% from the prior year.
• Liabilities and Shareholders Equity was $624.2 million for Q4 2025 at Adma Biologics, up from $568.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $624.2 million in Q4 2025 and bottomed at $232.8 million in Q2 2021.
• A 5-year average of $373.4 million and a median of $345.7 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity jumped 134.49% — and 2023, when it decreased 5.53%.
• Adma Biologics' Liabilities and Shareholders Equity stood at $276.3 million in 2021, then climbed by 26.14% to $348.5 million in 2022, then dropped by 5.53% to $329.2 million in 2023, then soared by 48.45% to $488.7 million in 2024, then increased by 27.74% to $624.2 million in 2025.
• Business Quant data shows ADMA's Liabilities and Shareholders Equity at $624.2 million in Q4 2025, $568.7 million in Q3 2025, and $558.4 million in Q2 2025.